SHC Q4 2025 Earnings Presentation

Page 1

Page 2

© 2026 Sotera Health Company | All Rights Reserved. Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures 1 Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this presentation refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are often characterized by the use of words such as “believes,” “estimates,” “expects,” “projects,” “may,” “intends,” “plans” or “anticipates,” or by discussions of strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance, achievements, or industry results, to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: a disruption in the availability or supply of, or increases in the price of, ethylene oxide (“EO”), Cobalt-60 (“Co-60”) or our other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions against Russia by the United States, Canada, the United Kingdom and/or the European Union; fluctuations in foreign currency exchange rates; evolving changes in environmental, health and safety regulations or preferences; health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60; the impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from our EO sterilization facilities, and the possibility that additional claims will be made in the future; allegations of our failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm; compliance with the extensive regulatory requirements to which we are subject, the related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals; adverse changes in industry trends; competition we face; market conditions and changes, including inflationary trends and the impact of tariffs, that impact our long-term supply contracts with variable price clauses and increase our cost of revenues; business continuity hazards, including supply chain disruptions, federal government shutdowns, and other risks associated with our operations; the risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable laws and potentially inconsistent laws and regulations in multiple jurisdictions; our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our leased facilities; our ability to attract and retain qualified employees; severe health events or environmental events; cybersecurity incidents, unauthorized data disclosures, and our dependence on information technology systems; the risks associated with the introduction of artificial intelligence technology; an inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into our business successfully; our ability to maintain effective internal control over financial reporting; our reliance on intellectual property rights to maintain our competitive position and the risk of claims from third parties that we have infringed or misappropriated, or are infringing or misappropriating, their intellectual property rights; our ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts with such laws and regulations; our ability to generate profitability in future periods; impairment charges on our goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives; the effects of unionization efforts and labor regulations in countries in which we operate; adverse changes to our tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations; and our significant leverage and how this significant leverage could adversely affect our ability to raise additional capital, limit our ability to react to challenges facing our Company or broader changes in our industry or the economy, limit our flexibility in operating our business through restrictions contained in our debt agreements and/or prevent us from meeting our obligations under our existing and future agreements governing our indebtedness. These forward-looking statements are based on current plans, estimates and projections, and therefore you should not place undue reliance on them. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them publicly in light of new information or future events, except as required by law. The inclusion of this forward-looking information should not be regarded as a representation by us or any other person that the future plans, estimates or expectations contemplated by us will be achieved. For additional discussion of these risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission (“SEC”), such as its Annual Report on Form 10-K and quarterly reports. If any of these trends, risks or uncertainties actually occur or continue, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline and you could lose all or part of your investment. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement. This presentation includes Adjusted EBITDA, Adjusted EBITDA Margin, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Adjusted EPS, Free Cash Flow, Net Debt and Net Leverage Ratio, which are unaudited financial measures that are not based on any standardized methodology prescribed by GAAP . Adjusted EBITDA, Adjusted EBITDA Margin, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Adjusted EPS, Free Cash Flow, Net Debt and Net Leverage Ratio may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Adjusted EBITDA, Adjusted EBITDA Margin, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Adjusted EPS, Free Cash Flow, Net Debt and Net Leverage Ratio should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP . This presentation refers to, and in other communications with investors the Company may refer to, net sales or revenues or other historical financial information on a “constant currency” basis, which is a non-GAAP financial measure defined in the Appendix to this presentation. We use these non-GAAP financial measures as the principal measures of our operating performance. Management believes these measures allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained without these measures and their disclosure. In addition, we believe these measures will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses these measurements in their financial analysis and operational decision-making and Adjusted EBITDA serves as the key metric for the attainment of our primary annual incentive program. These measures may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies. The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort. The Company cannot reconcile its expected Adjusted EBITDA, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Adjusted EPS, Free Cash Flow, and Net Leverage Ratio without unreasonable effort because certain items that impact net income, earnings per share and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time, including uncertainties caused by changes to the regulatory landscape, restructuring items and certain fair value measurements, all of which are potential adjustments for future earnings. This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company’s industry and estimated total and serviceable addressable markets. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified this market data. While we are not aware of any misstatements regarding any industry or similar data presented herein, such data involve risks and uncertainties and are subject to change based on various factors, including those described under the headings of “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K, and in the Company’s other SEC filings. In addition, projections, assumptions and estimates of the Company’s future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk. The Sotera Health name, our logo and other trademarks mentioned in this presentation are the property of their respective owners. All Company data and financial information included in this presentation is as of December 31, 2025, unless otherwise stated.

Page 3

Page 4

© 2026 Sotera Health Company | All Rights Reserved. 2025 Full-Year Highlights 3 (1) This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix. (2) CC = constant currency. 5.7%; 5.2% CC (1)(2) 8.2%; 7.8% CC 118bps to 51.0% $0.16 to $0.86  Delivered top- & bottom-line growth; marks 20th consecutive year of revenue growth  Improved Adjusted EBITDA margins by 118 basis points, to 51%, versus 2024  Free Cash Flow of $210M (1)  Strong results from annual customer satisfaction survey Performance Capital Markets Actions  Annual interest savings of $13M from Term Loan repricing and debt paydowns of $86M  Upsized revolver, increasing availability by $175M to $600M  Increased public float to 80% of outstanding shares  9% revenue growth from our XBU customers versus 2024  Sterigenics: ~8% YoY CC revenue growth driven by volume/mix improvement  Nordion: ~9% YoY CC revenue growth; secured a 25-year Class 1B license renewal  Nelson Labs: core lab testing growth; on track with cleanroom investment Advancing our Portfolio Governance  Named Lead Independent Director of the Board  Continued shareholder corporate responsibility outreach and engagement Net Revenues Adjusted EBITDA (1) Adjusted EBITDA Margin (1) Adjusted EPS (1)

Page 5

Page 6

© 2026 Sotera Health Company | All Rights Reserved. $153 $157 2024 2025 $549 $594 2024 2025 +2.7% / 0.5% CC +8.2% / +7.8% CC $0.21 $0.26 2024 2025 +$0.05 $0.70 $0.86 2024 2025 +$0.16 Revenue Adjusted EBITDA $ In millions, except Adjusted EPS and Adjusted EBITDA margin Consolidated Financial Performance 5 Adjusted EPS Fourth Quarter 52.7% 51.8% FY 2025 49.9% 51.0% $290 $303 2024 2025 $1,100 $1,164 2024 2025 +4.6% / +2.5% CC +5.7% / +5.2% CC 5

Page 7

© 2026 Sotera Health Company | All Rights Reserved. $179 $198 $100 $110 2024 2025Revenue Segment Income Sterigenics Financial Performance 6 $ In millions Fourth Quarter FY 2025 Revenue +10.6% / +8.0% CC Segment Income +10.4% / +7.8% CC Revenue +8.3% / +7.7% CC Segment Income +9.2% / +8.6% CC • The growth in fourth quarter revenue and segment income was driven by favorable pricing, volume/mix and changes in foreign currency exchange rates, with segment income growth partially offset by inflation. $698 $756 $378 $413 2024 2025Revenue Segment Income 55.5% 55.4% 54.2% 54.6%

Page 8

© 2026 Sotera Health Company | All Rights Reserved. $173 $188 $101 $108 2024 2025Revenue Segment Income $57 $50 $35 $29 2024 2025Revenue Segment Income Nordion Financial Performance 7 $ In millions Fourth Quarter FY 2025 Revenue -12.3% / -12.6% CC Segment Income -18.9% / -19.3% CC Revenue +8.2% / +9.1% CC Segment Income +6.3% / +6.9% CC • The change in fourth quarter revenue and segment income was primarily driven by unfavorable volume/mix due to the timing of cobalt-60 harvest schedules, partially offset by favorable pricing. Segment income margin was also impacted by unfavorable product mix. 62.1% 57.5% 58.4% 57.3%

Page 9

© 2026 Sotera Health Company | All Rights Reserved. $229 $220 $69 $73 2024 2025Revenue Segment Income $54 $55 $18 $18 2024 2025Revenue Segment Income Nelson Labs Financial Performance 8 $ In millions Fourth Quarter FY 2025 Revenue +2.3% / -0.2% CC Segment Income +1.9% / -1.2% CC Revenue -3.9% / -5.0% CC Segment Income +6.0% / +4.4% CC • The increase in fourth quarter revenue and segment income was driven by favorable pricing, improvement in core lab testing services and changes in foreign currency exchange rates, partially offset by a decline in Expert Advisory Services. Segment income growth was also partially offset by higher costs. 33.5% 33.4% 30.2% 33.3%

Page 10

© 2026 Sotera Health Company | All Rights Reserved. Net Leverage, Liquidity and Investments 9 $215 $179 $138 FY 2023 FY 2024 FY 2025 3.8x 3.7x 3.2x 12/31/23 12/31/24 12/31/25 $296 $277 $345 $400 $410 $592 12/31/23 12/31/24 12/31/25 Unrestricted Cash Revolver Availability $696 • As of 12/31/25, strong liquidity position of $937M • No outstanding borrowings on the revolving line of credit • Net Leverage Ratio improved to 3.2x as of 12/31/25 • Term Loan paydowns of $86M in 2025 • Sterigenics: 2 active capacity expansions; continued EO facility investments • Nordion: Cobalt-60 development projects • Nelson Labs: Pharma, cleanroom and embedded lab expansions $687 $937 $ In millions Liquidity Net Leverage (1) CapEx (1)

Page 11

Page 12

© 2026 Sotera Health Company | All Rights Reserved. Full-year 2026 Outlook (1) 11 (1) This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix. FY 2026 Outlook Net Revenues $1,233M to $1,251M +6.0% to 7.5% +5.0 to 6.5% CC Adjusted EBITDA $632M to $641M +6.5% to 8.0% +5.5 to 7.0% CC Interest Expense $135M to $145M Tax Rate Applicable to Adjusted Net Income (2) 27.0% to 29.0% Adjusted EPS $0.93 to $1.01 Weighted Average Diluted Shares 289M to 291M Capital Expenditures $175M to $225M

Page 13

© 2026 Sotera Health Company | All Rights Reserved. Additional 2026 Outlook Items 12 • Total company pricing expected to be approximately the mid-point of 3% - 4% long-term range • Foreign exchange benefit expected to be weighted toward 1H ’26, with largest impact expected in Q1’26 • Net leverage ratio expected to improve versus 12/31/25 • Outlook assumes no M&A activity General Commentary • Sterigenics: FY’26 CC revenue growth in the mid- to high-single digits, compared FY’25; Q1’26 CC revenue growth in the mid-single digits, compared to Q1‘25 • Nordion: FY’26 CC revenue growth in the low- to mid-single digits, compared to FY’25; 1H ’26 revenue expected to be between 40% to 45% of FY ’26 revenue; Q2’26 revenue heavier than Q1’26 • Nelson Labs: FY’26 CC revenue growth in low-single digits; Q1’26 CC revenue growth down low- to mid- single digits compared to Q1’25 Cadence Expectations

Page 14

Page 15

© 2026 Sotera Health Company | All Rights Reserved. Executing Against our Investor Day Commitments 14 Organic Revenue Growth (1) 5 - 7% 5.2% On track Adjusted EBITDA Growth (1) 5 - 8% 7.8% On track Adjusted EBITDA Margin Improvement 50 - 150bps 118bps On track Cumulative Free Cash Flow $500M - $600M $210M On track Net Leverage Ratio 2.0x – 3.0x 3.2x On track 2025-2027 Target FY 2025 Status (1) On a constant currency basis

Page 16

© 2026 Sotera Health Company | All Rights Reserved. a Corporate Responsibility Journey Since 2020 IPO 15 2021 2022 2023 2024  Developed corporate responsibility strategy and established formal governance  Gap Analysis and Materiality Matrix  Named SVP, Global Environment, Health and Safety (EHS)  Published Inaugural Corporate Responsibility Report  Formalized enterprise risk management program  Initiated GHG emissions, energy, and water withdrawal tracking  Expanded EHS Leadership  Published 2nd Corporate Responsibility Report  Reported baseline sustainability metrics  First fall cycle stockholder engagement  Named additional independent director  Published 3rd Corporate Responsibility Report  Enhanced sustainability metrics for full year 2022 and 2023  Named additional independent director 2025  Appointed Lead Independent Director  Private equity ownership at 20% as of 12/31/25  Completed shareholder engagement in 2H’25

Page 17

© 2026 Sotera Health Company | All Rights Reserved. 16 Excellence in serving our customers with end-to-end solutions Win in growth markets Driving operational excellence to enhance free cash flow Disciplined capital deployment 1 2 3 4 Strong Execution to Generate Value for Our Stakeholders Our Company Key Priorities

Page 18

Page 19

Page 20

© 2026 Sotera Health Company | All Rights Reserved. Non-GAAP Financial Measures 19 (unaudited) (dollars in thousands, except per share amounts) Three months ended December 31, Year ended December 31, 2024 2025 2023 2024 2025 Net income $ 12,323 $ 34,847 $ 51,376 $ 44,398 $ 77,949 Amortization of intangible assets 19,640 5,552 81,348 79,377 41,798 Share-based compensation(a) 8,173 7,603 32,364 36,896 31,068 Loss on refinancing of debt(b) 8 295 — 24,168 1,462 Loss (gain) on foreign currency and derivatives not designated as hedging instruments, net (c) 4,147 1,352 (1,552) 2,448 58 Business optimization expenses(d) 4,635 493 7,662 9,368 8,068 Professional services relating to EO sterilization facilities(e) 10,337 8,710 45,312 32,694 46,225 Illinois EO litigation settlements(f) — — — — 64,943 Georgia EO litigation settlement(g) — — 35,000 — — Accretion of asset retirement obligations(h) 724 583 2,413 2,638 2,321 Income tax provision (benefit) associated with pre-tax adjustments(i) (1,246) 15,603 (49,597) (33,487) (28,478) Adjusted Net Income 58,741 75,038 204,326 198,500 245,414 Interest expense, net 40,960 35,048 142,878 164,691 155,722 Depreciation(j) 19,346 26,904 76,577 82,420 94,630 Income tax provision applicable to Adjusted Net Income(k) 33,887 20,047 104,248 102,963 98,035 Adjusted EBITDA(l) $ 152,934 $ 157,037 $ 528,029 $ 548,574 $ 593,801 Net Revenues $ 290,203 $ 303,441 $1,049,288 $1,100,441 $1,163,617 Adjusted EBITDA Margin 52.7 % 51.8 % 50.3 % 49.9 % 51.0 % Weighted average number of shares outstanding Basic 283,260 284,256 281,008 282,784 283,956 Diluted 285,817 287,554 283,222 284,906 286,421 Earnings per share Basic $ 0.04 $ 0.12 $ 0.18 $ 0.16 $ 0.27 Diluted 0.04 0.12 0.18 0.16 0.27 Adjusted earnings per share Basic $ 0.21 $ 0.26 $ 0.73 $ 0.70 $ 0.86 Diluted 0.21 0.26 0.72 0.70 0.86

Page 21

© 2026 Sotera Health Company | All Rights Reserved. Non-GAAP Financial Measures (continued) 20 a) Represents share-based compensation expense to employees and Non-Employee Directors. b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the refinancing activity for the Term Loans, the Secured Notes and the Revolving Credit Facility.. c) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii)non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion. d) Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with the secondary offerings and shareholder engagement. e) Represents litigation and other professional fees associated with our EO sterilization facilities. f) Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025. g) Represents the cost to settle 79 pending EO claims in Georgia under a settlement entered into on December 21, 2023. h) Represents non-cash accretion of asset retirement obligations related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset. i) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities, and unusual items from our presentation of adjusted net income. j) Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities. k) Represents the difference between the income tax provision as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (i). l) $24.1 million, $27.2 million, $94.1 million, $97.1 million and $99.9 million of the adjustments for the for the three months ended December 31, 2024 and 2025 and years ended December 31, 2023, 2024 and 2025, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.

Page 22

© 2026 Sotera Health Company | All Rights Reserved. Non-GAAP Financial Measures 21 (unaudited) a) Represents litigation and other professional fees associated with our EO sterilization facilities. b) Represents the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into in April 2025. c) Represents the tax effects of the litigation and other professional fees associated with our EO sterilization facilities and the costs to settle the EO claims in Illinois as noted in (a) and (b) above. Year Ended December 31, (in thousands of U.S. dollars) 2025 Net cash provided by operating activities 287,195 Purchases of property, plant and equipment, net (138,018) Other investing activities 2,800 Professional services relating to EO sterilization facilities(a) 46,225 EO litigation settlements(b) 30,943 Tax effect of EO litigation settlements and litigation costs(c) (19,292) Free Cash Flow 209,853

Page 23

© 2026 Sotera Health Company | All Rights Reserved. Non-GAAP Financial Measures (continued) 22 (1) Represents Adjusted EBITDA for the years ended December 31, 2023, 2024 and 2025, respectively. Refer to the reconciliations of Adjusted EBITDA to net income for additional detail. As of December 31, 2023 2024 2025 Current portion of long-term debt $ 4,797 14,803 13,973 Long-term debt less current portion 2,223,674 2,208,100 2,126,724 Current portion of finance leases 8,771 2,923 3,465 Finance leases less current portion 63,793 95,286 93,835 Total Debt 2,301,035 2,321,112 2,237,997 Less: cash and cash equivalents (296,407) (277,242) (344,621) Total Net Debt $ 2,004,628 $ 2,043,870 1,893,376 Adjusted EBITDA(1) $ 528,029 $ 548,574 $ 593,801 Net Leverage 3.8x 3.7x 3.2x (unaudited) (dollars in thousands)

Page 24

© 2026 Sotera Health Company | All Rights Reserved. Non-GAAP Financial Measures Definitions 23 • Adjusted Net Income is defined as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period. • Adjusted EBITDA is defined as Adjusted Net Income before interest expense, depreciation (including depreciation of Co-60 used in our operations) and income tax provision applicable to Adjusted Net Income. • Adjusted EBITDA margin is equal to Adjusted EBITDA divided by net revenues. • Segment income margin is equal to segment income divided by net segment revenues. • Adjusted EPS is defined as Adjusted Net Income divided by the weighted average number of diluted shares outstanding. • Free Cash Flow is defined as cash provided by operating activities minus capital expenditures and excludes the tax effected impact of EO litigation settlements and EO litigation defense costs. • Net Debt is equal to our total debt net of unamortized debt issuance costs and debt discounts, less cash and cash equivalents. • Net Leverage Ratio is equal to Net Debt divided by Adjusted EBITDA. • We calculate constant currency net revenues by translating prior year net revenues in local currency at the average exchange rates applicable for the current period. The translated results are then used to determine year-over-year percentage increases or decreases. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign currency exchange rates.

Slides